HIMS Blowout Q3 Leads To Substantial Fair Value Bump

Hims & Hers delivered yet another blowout result for Q3 - this one the most impressive yet. Revenue growth accelerated to 77%, on the back of both the GLP-1 weight loss drug launch, and the 44% subscriber growth it helped drive. Even ex-GLP sales, revenues soared 40%. The weight loss drug launch has also supercharged the Hers brand, giving the company yet another growth avenue. The stock is up over 150% since we added it a year ago, but now looks like as good a time as ever to add. The fair value gets a substantial bump from $21 to $28.

Watch List

RDDT 9.50%
NTNX 32.17%
CRWD 69.63%
SE 33.25%
SNOW 9.94%
APPF 7.88%
PINS -23.46%

Buy List

SEMR -39.03%
TSM -36.66%
GOOG -51.12%
NYAX -54.88%
MSFT -30.39%
ASR -25.76%
FLYW -36.58%
HRMY -55.44%
YOU -35.76%
ABNB -31.01%
MELI -33.36%
ADBE -40.47%

Hold List

VTEX -16.16%
ZETA -19.22%
ODD -24.43%
CELH 47.00%
TOST 18.93%
CPNG -15.13%
HIMS -10.80%
PAYC -21.41%
MNDY 15.41%
GLBE -18.52%
ZS 27.02%
V -4.06%
ADSK -0.77%
NOW -0.48%
FTNT -3.84%
TEAM -1.77%